Two companies have been recommended by a Japanese health ministry expert panel to develop and sell products using induced pluripotent stem cells (iPS cells). These cells can transform into nerve, muscle, and other body cells, potentially restoring lost functions. Cuorips, a startup from Osaka University, developed cardiomyocyte sheets for treating ischemic cardiomyopathy, while Sumitomo Pharma applied to use iPS cells in Parkinson’s disease treatments.
The development of iPS cells has been rapid since Kyoto University Professor Yamanaka Shinya first announced their generation in 2006. National support in research funding and systems have contributed to this progress. However, the panel emphasized that success will depend on the products’ efficacy and safety verification through further studies involving treated patients over seven years.
The Japanese government is expected to approve the recommendation within one to two months. This move marks a significant step towards practical use of iPS cell-derived products worldwide.
Source: https://www3.nhk.or.jp/nhkworld/en/news/20260219_21